Form 4: Ultragenyx Exec Sells Shares Under 10b5-1 Plan

Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc., reported a sale of 4,683 shares of common stock on April 1, 2026, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Howard Horn, the Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (RARE), has reported a transaction involving company stock.
• On April 1, 2026, Horn sold 4,683 shares of common stock at a price of $20.97 per share.
• This transaction was conducted under a Rule 10b5-1 trading plan, which is designed to comply with affirmative defense conditions for insider trading.
• Following this sale, Horn beneficially owns 80,351 shares of common stock.
• The filing also notes that this ownership includes previously reported shares of common stock underlying Restricted Stock Units (RSUs) that are subject to vesting conditions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the sale of shares by a key executive, even though it was conducted under a 10b5-1 plan. This type of transaction can sometimes lead to investor apprehension.

Negatives

• A significant number of shares were sold by a key executive.

Risks

• The sale of shares by a Chief Financial Officer could be interpreted negatively by the market, potentially impacting investor confidence.
• The underlying reasons for the sale, even if under a 10b5-1 plan, might lead to speculation about the executive's personal outlook on the company's future performance.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding the company's future financial performance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting stock sales by executives, especially CFOs, are common and often executed under pre-arranged 10b5-1 plans to avoid insider trading concerns. However, the volume and timing of such sales can still influence market perception, particularly in the biotechnology sector where company-specific news and executive confidence play a significant role.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the sale by the CFO with caution, potentially leading to short-term market reactions, despite the 10b5-1 plan. The continued beneficial ownership of a substantial number of shares may offer some reassurance.
• Employees: May interpret the sale as a signal from management, potentially affecting morale or their own investment decisions in company stock.
• Creditors: Unlikely to be directly impacted by this executive stock transaction.

Key Dates

Recommendation

The filing reports a stock sale by the CFO under a 10b5-1 plan, which is a routine transaction. While such sales can sometimes create short-term negative sentiment, the fact that it's under a pre-arranged plan and the executive retains a significant number of shares suggests no immediate fundamental change in the company's outlook. Therefore, a 'hold' recommendation is appropriate, pending further company-specific developments.

Keywords

Ultragenyx Pharmaceutical, RARE, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Howard Horn, Chief Financial Officer, Beneficial Ownership, Common Stock